Qurient Co., Ltd. engages in the development of novel therapeutics. Its research and development pipeline includes multiple drug resistance tuberculosis, atopic dermatitis, asthma, and cancer. The company was founded by Ki-Yean Nam on July 2, 2008 and is headquartered in Seongnam-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company